Establishment and Clinical Application of Risk Classification Model Based on Molecular Typing of Medulloblastoma in Children

NCT ID: NCT05406947

Last Updated: 2023-02-08

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 350 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-01-30
• Study Completion Date: 2030-12-31

Brief Summary

The purpose of this study:(1) Development of a new risk classification model for childhood medulloblastoma. (2) Evaluation and improvement of existing individualized treatment protocols.

Detailed Description

Medulloblastoma (medulloblastoma, MB) is the most common intracranial malignant tumor in children, accounting for 20% of all central nervous system tumors in children, seriously affecting the quality of life and life span of children. Based on a retrospective analysis of previous MB cases in our center, we found that the clinical prognosis of previous MB patients in our center was worse than that in foreign countries, with an overall five-year survival rate of about 65%, and nearly 30% of the patients had tumor recurrence and metastasis within 2 years after the operation, and the prognosis was poor. We analyzed the possible reasons as follows: (1) the compliance to radiotherapy and chemotherapy in children with MB in our center was poor, and some of the patients only completed radiotherapy and had poor compliance with chemotherapy; (2) due to the lack of family doctor system, the tumor of the newly diagnosed patients was huge, which seriously affected the important brain function and clinical prognosis; (3) the patients were not followed up strictly and regularly after operation to monitor tumor recurrence, which led to poor treatment effect after recurrence.

(4) the unified treatment standard has not been formed yet, and the treatment mode for patients is complex.

As the largest neurosurgery and pediatric neurosurgery center in China, the center intends to prospectively establish a high-quality homogeneous MB observation cohort in children, make use of the center's case resources and biological sample processing advantages, and carry out accurate treatment research on children's MB through regular follow-up and systematic management of the clinical cohort.

Conditions

Medulloblastoma, Childhood

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Low risk group

Based on clinicopathological diagnosis and molecular pathological diagnosis, the children were classified into low risk groups, individualized radiotherapy and chemotherapy plan was made, and a perfect registration and follow-up system was established.

Prospective observational study, no intervention

Intervention Type: OTHER

Prospective observational study, no intervention

Middle risk group

Based on clinicopathological diagnosis and molecular pathological diagnosis, the children were classified into middle risk groups, individualized radiotherapy and chemotherapy plan was made, and a perfect registration and follow-up system was established.

Prospective observational study, no intervention

Intervention Type: OTHER

Prospective observational study, no intervention

High risk group

Based on clinicopathological diagnosis and molecular pathological diagnosis, the children were classified into high risk groups, individualized radiotherapy and chemotherapy plan was made, and a perfect registration and follow-up system was established.

Prospective observational study, no intervention

Intervention Type: OTHER

Prospective observational study, no intervention

Interventions

Prospective observational study, no intervention

Prospective observational study, no intervention

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Age 0.5-18 years (except neonates).
• Pathologically confirmed medulloblastoma.
• Not having received any other relevant treatment before surgery.
• Completion of enhanced MRI of the head and spinal cord.
• Availability of tumor samples and determination of molecular typing.
• Postoperative KPS score ≥ 70.
• Voluntary enrollment in the group and the ability to receive long-term follow-up.
• The patient or the patient's family voluntarily signed the informed consent form.

Exclusion Criteria

• Patients who have recently received other drugs or radiation therapy.
• Patients suffering from acute or chronic infectious diseases
• Patients suffering from neurological or psychiatric diseases or mental disorders that cannot be easily controlled, or poor compliance.
• Patients who cannot receive enhanced MRI scans.
• Other conditions that the investigator believes make the patient unfit to participate in this trial.

• Minimum Eligible Age: 6 Months
• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Beijing Neurosurgical Institute

OTHER

Sponsor Role: collaborator

Beijing Children's Hospital

OTHER

Sponsor Role: collaborator

Beijing Shijitan Hospital, Capital Medical University

OTHER

Sponsor Role: collaborator

Xuanwu Hospital, Beijing

OTHER

Sponsor Role: collaborator

Peking University Third Hospital

OTHER

Sponsor Role: collaborator

Beijing Tiantan Hospital

OTHER

Sponsor Role: lead

Responsible Party

Tianyongji

Director

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Yongji Tian, MD

Role: PRINCIPAL_INVESTIGATOR

Beijing TianTanHospital, China Capital Medical University

FU ZHAO, MD

Role: PRINCIPAL_INVESTIGATOR

Beijing Neurosurgical Institute

Central Contacts

yongji TIAN, MD

Role: CONTACT

tianyongji@bjtth.org

15801593549

Other Identifiers

ChiCTR2200058760

Identifier Type: -

Identifier Source: org_study_id